| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000.
|
Lancet
|
2012
|
25.96
|
|
2
|
Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis.
|
N Engl J Med
|
2006
|
9.93
|
|
3
|
Effect of human rotavirus vaccine on severe diarrhea in African infants.
|
N Engl J Med
|
2010
|
6.56
|
|
4
|
Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial.
|
Lancet
|
2010
|
5.43
|
|
5
|
Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine.
|
Rev Med Virol
|
2004
|
5.20
|
|
6
|
Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial.
|
Lancet
|
2010
|
4.26
|
|
7
|
Efficacy of a Low-Cost, Heat-Stable Oral Rotavirus Vaccine in Niger.
|
N Engl J Med
|
2017
|
3.22
|
|
8
|
Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children.
|
N Engl J Med
|
1983
|
3.00
|
|
9
|
Rotavirus stability and inactivation.
|
J Gen Virol
|
1979
|
2.48
|
|
10
|
Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial.
|
Lancet
|
2014
|
2.35
|
|
11
|
Seasonality of rotavirus disease in the tropics: a systematic review and meta-analysis.
|
Int J Epidemiol
|
2008
|
2.14
|
|
12
|
Comparison of mucosal and systemic humoral immune responses and subsequent protection in mice orally inoculated with a homologous or a heterologous rotavirus.
|
J Virol
|
1994
|
2.03
|
|
13
|
Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea.
|
J Infect Dis
|
1993
|
1.63
|
|
14
|
Development of candidate rotavirus vaccines derived from neonatal strains in India.
|
J Infect Dis
|
2005
|
1.52
|
|
15
|
Multicenter, hospital-based surveillance of rotavirus disease and strains among indian children aged <5 years.
|
J Infect Dis
|
2009
|
1.49
|
|
16
|
Global, Regional, and National Estimates of Rotavirus Mortality in Children <5 Years of Age, 2000-2013.
|
Clin Infect Dis
|
2016
|
1.36
|
|
17
|
Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
|
Vaccine
|
2012
|
1.31
|
|
18
|
Temperature-dependent transmission of rotavirus in Great Britain and The Netherlands.
|
Proc Biol Sci
|
2009
|
1.15
|
|
19
|
Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life.
|
Vaccine
|
2014
|
1.12
|
|
20
|
Use of formative research in developing a knowledge translation approach to rotavirus vaccine introduction in developing countries.
|
BMC Public Health
|
2007
|
1.11
|
|
21
|
Protection against rotavirus disease after natural rotavirus infection. US Rotavirus Vaccine Efficacy Group.
|
J Infect Dis
|
1994
|
1.08
|
|
22
|
Minimal infective dose of rotavirus.
|
Arch Virol
|
1987
|
1.08
|
|
23
|
Transplacental rotavirus IgG interferes with immune response to live oral rotavirus vaccine ORV-116E in Indian infants.
|
Vaccine
|
2013
|
1.07
|
|
24
|
A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial.
|
J Infect Dis
|
2009
|
1.07
|
|
25
|
Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial.
|
Vaccine
|
2006
|
1.05
|
|
26
|
Recommendations for rotavirus vaccination: A worldwide perspective.
|
Vaccine
|
2010
|
0.89
|
|
27
|
Rotavirus-specific antibody response in saliva of infants with rotavirus diarrhea.
|
J Infect Dis
|
1990
|
0.87
|
|
28
|
Discovery of rotavirus: Implications for child health.
|
J Gastroenterol Hepatol
|
2009
|
0.86
|
|
29
|
Reductions in cross-neutralizing antibody responses in infants after attenuation of the human rotavirus vaccine candidate 89-12.
|
J Infect Dis
|
2006
|
0.85
|
|
30
|
Rapid inactivation of rotaviruses by exposure to acid buffer or acidic gastric juice.
|
J Gen Virol
|
1985
|
0.81
|
|
31
|
Impact of Rotavirus Vaccination on Diarrheal Hospitalizations in Children Aged <5 Years in Lusaka, Zambia.
|
Clin Infect Dis
|
2016
|
0.81
|
|
32
|
Immunogenicity of tetravalent rhesus rotavirus vaccine administered with buffer and oral polio vaccine.
|
Am J Dis Child
|
1991
|
0.81
|
|
33
|
Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation.
|
Pediatr Infect Dis J
|
2003
|
0.81
|
|
34
|
A Preliminary Assessment of Rotavirus Vaccine Effectiveness in Zambia.
|
Clin Infect Dis
|
2016
|
0.80
|
|
35
|
Association of Maternal Immunity with Rotavirus Vaccine Immunogenicity in Zambian Infants.
|
PLoS One
|
2016
|
0.79
|
|
36
|
Immunogenicity of a live-attenuated human rotavirus RIX4414 vaccine with or without buffering agent.
|
Hum Vaccin
|
2010
|
0.76
|
|
37
|
ROTAVAC(®) does not interfere with the immune response to childhood vaccines in Indian infants: A randomized placebo controlled trial.
|
Heliyon
|
2017
|
0.76
|
|
38
|
Feasibility of using regional sentinel surveillance to monitor the rotavirus vaccine impact, effectiveness and intussusception incidence in the African Region.
|
Vaccine
|
2017
|
0.75
|
|
39
|
Intussusception Rates Before and After the Introduction of Rotavirus Vaccine.
|
Pediatrics
|
2016
|
0.75
|